- Email: [email protected]
Non-hormonal treatment of vasomotor symptoms in female patients with and after breast carcinoma
160
Abstracts / Maturitas 81 (2015) 144–190
est improvement was noticed in two out of four assessed patients. More results will be presented at the time of the meeting. Conclusion: Fractional CO2 laser treatment may be a promising alternative to local oestrogen in patients with vaginal atrophy in breast cancer patients. Nevertheless, it may be used before severe atrophy is installed.
P46
http://dx.doi.org/10.1016/j.maturitas.2015.02.179
Anemo Menopause Center, Nice, France
P45
Every year there are 53,000 new cases of breast cancer in France. The tumour is hormone-sensitive in around two-thirds of all cases. Restoring the quality of life of these patients is key to their wellbeing. The innocuousness and harmlessness of a purified cytoplasm of pollen (PCP) obtained from selected pollen grains by a patented procedure, free of allergens, has been demonstrated in numerous studies. The effectiveness of the mixture of purified cytoplasm of pollens (PCP) in the treatment of VMS was demonstrated in a randomised, double-blind, controlled study against a placebo. It is effective in the case of vasomotor symptoms (VMS) during the periand post-menopause, especially in women with and after breast cancer. PCP contains neither phytoestrogens nor hormones. It therefore has no hormonal effects, does not activate the oestrogen receptors and does not stimulate the proliferation of cancer cells. No oestrogenic effect could be demonstrated in a further assay in which the capacity of the PCP to bind to the oestrogen receptors was tested using MCF7 and 293T cells. Blood tests on FSH, oestrogens, testosterone and SHBG in further studies showed no change in concentrations in female patients who were treated with PCP. The vasomotor symptoms are reinforced and/or intensified by Tamoxifen. Tamoxifen is broken down by the cytochrome P450 2D6 to form 4-hydroxytamoxifen and other active metabolites. Anti-depressants (Fluoxetine and Paroxetine) and selective serotonin reuptake inhibitors (SSRI) have been prescribed to mitigate Tamoxifen-induced VMS. However, SSRI are powerful CYP2D6 inhibitors and can reduce the effectiveness of Tamoxifen. In contrary, there are no pharmacological interactions between the pollen extract and the CYP2D6 enzyme system. No inhibition of the enzymes was found at up to five times the daily dosage. These PCP appear to be a non-oestrogenic alternative to hormone therapy for women with VMS, even for women with and after breast cancer.
Polycarbophilic vaginal moisturizing gel for the relief of severe symptoms of vulvovaginal atrophy Ramón Usandizaga 1,∗ , María de la Calle 1 , José Estévez 2 , Ibone Huerta 3 , Juan Luis Delgado 4 1
Hospital Universitario La Paz, Madrid, Spain Hospital Universitario Marqués de Valdecilla, Santander, Spain 3 Italfarmaco, S.A., Madrid, Spain 4 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain 2
Vaginal moisturizers are used for symptomatic relief of vulvovaginal atrophy (VVA) caused by estrogen deficiency. The quality of life of postmenopausal women can be negatively affected with these symptoms and it should not be underestimated. Current Guidelines advice on the regular use of long acting non-hormonal moisturizers as first-line therapies to alleviate symptoms, being dryness and dyspareunia the most frequent and bothersome. The efficacy of a polycarbophilic vaginal moisturizing gel (Ainara® ) for relieving severe symptoms of VVA was evaluated in 32 postmenopausal women suffering from severe vaginal dryness or severe dyspareunia. All women received 1 g of the gel daily during 3 weeks and twice weekly up to 12 weeks. Symptoms were evaluated with a validated numeric scale (0 = absent, 1 = mild, 2 = moderate and 3 = severe) at baseline and at after 3 and 12 weeks of treatment. Significant change in the intensity of the symptoms was evaluated using Wilcoxon tests. The percentage of women that improved the symptoms was also calculated. After 3 weeks, 78% women improved vaginal dryness and 65% improved dyspareunia. After 12 weeks, 78% women improved vaginal dryness and 69% improved dyspareunia. The intensity of the vaginal dryness decreased from 2.8 to 1.6 (p < 0.001) after 3 weeks and to 1.3 (p < 0.001) after 12 weeks, while the intensity of the dyspareunia decreased from 2.7 to 1.5 (p = 0.002) and to 1.2 (p < 0.001) respectively. Similar results were obtained in the subgroup of women with both dyspareunia and vaginal dryness severe. These results show the efficacy of a polycarbophilic vaginal moisturizing gel for the significant relief of severe symptoms of VVA to a level close to mild after 12 weeks treatment. These results also highlight the potential use of this product in women with severe symptoms that do not want to use estrogens or women in whom estrogens are contraindicated such as those with a history of hormone-dependent cancers, or following pelvic radiotherapy. http://dx.doi.org/10.1016/j.maturitas.2015.02.180
Non-hormonal treatment of vasomotor symptoms in female patients with and after breast carcinoma René Druckmann
http://dx.doi.org/10.1016/j.maturitas.2015.02.181 P47 The comparison between the effects of hyaluronic acid vaginal suppository and vitamin E on the treatment of atrophic vaginitis in menopausal women Zahra Abbaspoor 1,∗ , Sara Ziagham 2 , Mohamad Reza Abbaspour 1 1 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Islamic Republic of Iran 2 Ahvaz University of Medical Sciences, Department of Midwifery, Shoshtar, Islamic Republic of Iran
Background: Urogenital atrophy is a common problem after menopause and quality of life in post-menopause is seriously affected by the symptoms associated with vaginal atrophy. The aim of this study was to compare the effectiveness of the vaginal suppository of hyaluronic acid and vitamin E in atrophic vaginitis treatment.
Abstracts / Maturitas 81 (2015) 144–190
est improvement was noticed in two out of four assessed patients. More results will be presented at the time of the meeting. Conclusion: Fractional CO2 laser treatment may be a promising alternative to local oestrogen in patients with vaginal atrophy in breast cancer patients. Nevertheless, it may be used before severe atrophy is installed.
P46
http://dx.doi.org/10.1016/j.maturitas.2015.02.179
Anemo Menopause Center, Nice, France
P45
Every year there are 53,000 new cases of breast cancer in France. The tumour is hormone-sensitive in around two-thirds of all cases. Restoring the quality of life of these patients is key to their wellbeing. The innocuousness and harmlessness of a purified cytoplasm of pollen (PCP) obtained from selected pollen grains by a patented procedure, free of allergens, has been demonstrated in numerous studies. The effectiveness of the mixture of purified cytoplasm of pollens (PCP) in the treatment of VMS was demonstrated in a randomised, double-blind, controlled study against a placebo. It is effective in the case of vasomotor symptoms (VMS) during the periand post-menopause, especially in women with and after breast cancer. PCP contains neither phytoestrogens nor hormones. It therefore has no hormonal effects, does not activate the oestrogen receptors and does not stimulate the proliferation of cancer cells. No oestrogenic effect could be demonstrated in a further assay in which the capacity of the PCP to bind to the oestrogen receptors was tested using MCF7 and 293T cells. Blood tests on FSH, oestrogens, testosterone and SHBG in further studies showed no change in concentrations in female patients who were treated with PCP. The vasomotor symptoms are reinforced and/or intensified by Tamoxifen. Tamoxifen is broken down by the cytochrome P450 2D6 to form 4-hydroxytamoxifen and other active metabolites. Anti-depressants (Fluoxetine and Paroxetine) and selective serotonin reuptake inhibitors (SSRI) have been prescribed to mitigate Tamoxifen-induced VMS. However, SSRI are powerful CYP2D6 inhibitors and can reduce the effectiveness of Tamoxifen. In contrary, there are no pharmacological interactions between the pollen extract and the CYP2D6 enzyme system. No inhibition of the enzymes was found at up to five times the daily dosage. These PCP appear to be a non-oestrogenic alternative to hormone therapy for women with VMS, even for women with and after breast cancer.
Polycarbophilic vaginal moisturizing gel for the relief of severe symptoms of vulvovaginal atrophy Ramón Usandizaga 1,∗ , María de la Calle 1 , José Estévez 2 , Ibone Huerta 3 , Juan Luis Delgado 4 1
Hospital Universitario La Paz, Madrid, Spain Hospital Universitario Marqués de Valdecilla, Santander, Spain 3 Italfarmaco, S.A., Madrid, Spain 4 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain 2
Vaginal moisturizers are used for symptomatic relief of vulvovaginal atrophy (VVA) caused by estrogen deficiency. The quality of life of postmenopausal women can be negatively affected with these symptoms and it should not be underestimated. Current Guidelines advice on the regular use of long acting non-hormonal moisturizers as first-line therapies to alleviate symptoms, being dryness and dyspareunia the most frequent and bothersome. The efficacy of a polycarbophilic vaginal moisturizing gel (Ainara® ) for relieving severe symptoms of VVA was evaluated in 32 postmenopausal women suffering from severe vaginal dryness or severe dyspareunia. All women received 1 g of the gel daily during 3 weeks and twice weekly up to 12 weeks. Symptoms were evaluated with a validated numeric scale (0 = absent, 1 = mild, 2 = moderate and 3 = severe) at baseline and at after 3 and 12 weeks of treatment. Significant change in the intensity of the symptoms was evaluated using Wilcoxon tests. The percentage of women that improved the symptoms was also calculated. After 3 weeks, 78% women improved vaginal dryness and 65% improved dyspareunia. After 12 weeks, 78% women improved vaginal dryness and 69% improved dyspareunia. The intensity of the vaginal dryness decreased from 2.8 to 1.6 (p < 0.001) after 3 weeks and to 1.3 (p < 0.001) after 12 weeks, while the intensity of the dyspareunia decreased from 2.7 to 1.5 (p = 0.002) and to 1.2 (p < 0.001) respectively. Similar results were obtained in the subgroup of women with both dyspareunia and vaginal dryness severe. These results show the efficacy of a polycarbophilic vaginal moisturizing gel for the significant relief of severe symptoms of VVA to a level close to mild after 12 weeks treatment. These results also highlight the potential use of this product in women with severe symptoms that do not want to use estrogens or women in whom estrogens are contraindicated such as those with a history of hormone-dependent cancers, or following pelvic radiotherapy. http://dx.doi.org/10.1016/j.maturitas.2015.02.180
Non-hormonal treatment of vasomotor symptoms in female patients with and after breast carcinoma René Druckmann
http://dx.doi.org/10.1016/j.maturitas.2015.02.181 P47 The comparison between the effects of hyaluronic acid vaginal suppository and vitamin E on the treatment of atrophic vaginitis in menopausal women Zahra Abbaspoor 1,∗ , Sara Ziagham 2 , Mohamad Reza Abbaspour 1 1 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Islamic Republic of Iran 2 Ahvaz University of Medical Sciences, Department of Midwifery, Shoshtar, Islamic Republic of Iran
Background: Urogenital atrophy is a common problem after menopause and quality of life in post-menopause is seriously affected by the symptoms associated with vaginal atrophy. The aim of this study was to compare the effectiveness of the vaginal suppository of hyaluronic acid and vitamin E in atrophic vaginitis treatment.